Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura

Blood

Volumn 112, Issue 1, 2008, Pages 11-18

  Sadler, J Evan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADAMTS13 DEFICIENCY; BLOOD TRANSFUSION; CARDIOGENIC SHOCK; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DIFFERENTIAL DIAGNOSIS; ENZYME ASSAY; ENZYME DEFICIENCY; HEMOLYTIC ANEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; PATHOGENESIS; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RELAPSE; REMISSION; REVIEW; SALVAGE THERAPY; STRONGYLE INFECTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPSHAW SCHULMAN SYNDROME; BLOOD; IMMUNOLOGY; METABOLISM;

ADAM PROTEINS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; VON WILLEBRAND FACTOR;

EID: 47249144803     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-078170     Document Type: Review

References (84)

1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc. 1924;24: 21-24.
2. Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. Arch Intern Med. 1925: 36:89-93.
3. Amorosi EL. Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45:139-159.
4. Lederer M. A form of acute hemolytic anemia probably of infectious origin. Am J Med Sci. 1925: 170:500-510.
5. Lederer M. Three additional cases of acute hemolytic (infectious) anemia. Am J Med Sci. 1930: 179:228-236.
6. Rubinstein MA, Kagan BM, Macgillviray MH, Merliss R, Sacks H. Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions. Ann Intern Med. 1959;51:1409-1419.
7. Bukowski RM, Hewlett JS, Harris JW, et al. Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura. Semin Hematol. 1976;13:219-232.
8. Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood. 1977;50:413-417.
9. Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med. 1977;297:1386-1389.
10. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura: Canadian Apheresis Study Group. N Engl J Med. 1991:325:393-397.
11. Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis, I: a factor in normal human plasma required for platelet production: chronic thrombocytopenia due to its deficiency. Blood. 1960:16:943-957.
12. Upshaw JD Jr. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med. 1978;298:1350-1352.
13. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII : Von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982:307: 1432-1435.
14. Tsai H-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87:4235-4244.
15. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223-4234.
16. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic re-
17. lapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097-3103.
18. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339:1585-1594.
19. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome. N Engl J Med. 1998;339:1578-1584.
20. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98:1662-1666.
21. Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino add sequence of purified von Willebrand factor-cleaving protease. Blood. 2001;98:1654-1661.
22. Soejima K, Mimura N, Hirashima M, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem. 2001;130:475-480.
23. Zheng X, Chung D, Takayama TK. Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thromboticthrombocytopenic purpura. J Biol Chem. 2001;276:41059-41063.
24. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488-494.
25. Hurskainen TL, Hirohata S, Seldin MF, Apte SS. ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases: general features and genomic distribution of the ADAM-TS family. J Biol Chem. 1999;274: 25555-25563.
26. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003; 102:60-68.
27. Veyradier A, Obert B, HoullierA, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 2001;98:1765-1772.
28. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103:4043-4049.
29. Kremer Hovinga JA, Studt JD, Alberio L, Lammle B. von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol. 2004;41:75-82.
30. Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol. 2004;41:68-74.
31. Bohm M, Betz C, Miesbach W, et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol. 2005;129:644-652.
32. Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost. 2003;1:625-631.
33. Kavanagh D. Richards A. Atkinson JP. Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med. 2008;59:61-77.
34. Sarode R, McFarland JG, Flomenberg N, et al. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant. 1995;16:271-275.
35. van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantationassociated, thrombotic thrombocytopenic purpura. Blood. 1999;93:3798-3802.
36. Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, Tsai HM. Von Willebrand factorcleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. Hematol J. 2001;2:292-299.
37. Iwata H, Kami M, Hori A, Hamaki T, Takeuchi K, Mutou Y. An autopsy-based retrospective study of secondary thrombotic thrombocytopenic purpura. Haematologica. 2001;86:669-670.
38. Coppo P, Bengoufa D, Veyradier A, et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine. 2004;83:233-244.
39. Raife T, Atkinson B, Montgomery R, Vesely S, Friedman K. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion. 2004;44:146-150.
40. Coppo P, Wolf M, Veyradier A, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2006;132:66-74.
41. Tsai HM, Li A, Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab. 2001;47:387-392.
42. Tsai HM. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol. 2000;65:251-255.
43. Mori Y Wada H, Gabazza EC, et al. Predicting response to plasma exchange in patients with thromboticthrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion. 2002;42:572-580.
44. Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADAMTS 13 antibody features (lg isotype, titer, and inhibitory effect} in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood. 2007; 109;2815-2822.
45. Peyvandi F. Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies are markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica. 2008;93:69-76.
46. George JN. Clinical practice: thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354: 1927-1935.
47. Sadler JE. Thrombotic thrombocytopenic purpura: a moving target. Hematology Am Soc Hematol Educ Program. 2006;2006:415-420.
48. Mannucci PM, Peyvandi F. TTP and ADAMTS13: when is testing appropriate? Hematology Am Soc Hematol Educ Program. 2007;2007:121-126.
49. Tsai H-M, Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol. 2003;70:183-185.
50. Downes KA, Yomtovian R, Tsai HM, Silver B, Rutherford C, Sarode R. Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. J Clin Apher. 2004:19:86-89.
51. Adachi T, Matsushita T, Ichihashi R.etal. High titer of ADAMTS13 inhibitor associated with thrombotic microangiopathy of the gut and skeletal muscle after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2006;83:415-419.
52. Pham PT, Danovitoh GM, Wilkinson AH, at al. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation. 2002;74: 1077-1080.
53. Mal H, Veyradier A, Brugiere O, et al. Thrombotic microangiopathy with acquired deficiency in ADAMTS 13 activity in lung transplant recipients. Transplantation. 2006;81:1628-1632.
54. Ulinski T, CharpentierA, Colombat M, et al. From humoral rejection to generalized thrombotic microangiopathy: role of acquired ADAMTS13 deficiency in a renal allograft recipient. Am J Transplant. 2006;6:3030-3036.
55. Ahmed S, Siddiqui AK, Chandrasekaran V. Correlation of thrombotic thrombocytopenic purpura disease activity with von Willibrand factorcleaving protease level in ulcerative colitis. Am J Med. 2004;116:786-787. 55. Rick ME, Austin H, Leitman SF, Krizek DM, Aronson DL. Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura. Am J Hematol. 2004;75:96-100.
56. Fujisaki K, Masutani K, Yoshimitsu T, et al. Thrombotic thrombocytopenic purpura associated with polyarteritis nodosa. Clin Nephrol. 2005;64:305-310.
57. Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci PM. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica. 2003;88:1029-1034.
58. George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2003;10: 339-344.
59. Scully M, Starke R, Lee R, Mackie I, Machin S, Cohen H. Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinolysis. 2006;17:459-463.
60. Allford SL, Harrison P, Lawrie AS, Liesner R, MacKie IJ, Machin SJ. Von Willebrand factorcleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol. 2000;111:1215-1222.
61. Barbot J, Costa E, Guerra M, et al. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result
62. of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol. 2001: 113:649-651.
63. Kinoshita S, Yoshioka A, Park YD, et al. Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol. 2001;74:101-108. 63. SasaharaY, Kumaki S, Ohashi Y, et al. Deficient activity of von Willebrand factor-cleaving protease in patients with Upshaw-Schulman syndrome. Int J Hematol. 2001;74:109-114.
64. Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. BrJ Haematol. 2007:136:451-461.
65. Adams M, Ward C, Thorn J, et al. Emerging technologies in hemostasis diagnostics: a report from the Australasian Society of Thrombosis and Haemostasis Emerging Technologies Group. Semin Thromb Hemost. 2007:33:226-234.
66. Miyata T, Kokame K, Banno F, Shin Y, Akiyama M. ADAMTS13 assays and ADAMTS13-deficient mice. CurrOpin Hematol. 2007:14:277-283.
67. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibodybased enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006;46:1444-1452.
68. Franchini M, Veneri D, Lippi G, Stenner R. The efficacy of rituximab in the treatment of inhibitorassociated hemostatic disorders. Thromb Haemost. 2006;96:119-125.
69. Heidel F, Lipka DB, von Auer C, Huber C, Scharrer I, Hess G. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost. 2007;97:228-233.
70. Millward PM, Bandarenko N, Chang PP, etal. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion. 2005;45: 1481-1486.
71. Gutterman LA, Kloster B, Tsai H-M. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis. 2002;28:385-391.
72. GalbuseraM, Bresin E, Noris M, etal. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood. 2005;106: 925-928.
73. Herbei L, Venugopal P. Recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab. Clin Adv Hematol Oncol. 2006;4:215-217, discussion 217-218.
74. Patino W, Sarode R. Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura. J Clin Apher. 2007;22:17-20.
75. Centers for Medicare and Medicaid Services Regulation number CMS-1392-P. Proposed Changes to the Hospital Outpatient Prospective Payment System and CY 2008 Payment Rates. Addendum A. http://www.cms.hhs.gov/HospitalOutpatient-PPS/ HORD/list.asp#TopOfPage. Accessed February 6, 2008.
76. Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med. 2005;353:1516-1522.
77. Rock G, Shumak K, Kelton J, et al. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange: Canadian Apheresis Study Group. Transfusion. 1992;32:710-714.
78. Howard MA, Williams LA, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpurahemolytic uremic syndrome. Transfusion. 2006; 46:154-156.
79. Zhang P, Pan W, Rux AH, Sachais BS, Zheng XL. The cooperative activity between the carboxylterminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood. 2007;110:1887-1894.
80. Klaus C, Plaimauer B, Studt JD, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood. 2004;103:4514-4519.
81. Luken BM, Turenhout EA, Hulstein JJ, Van Mourik JA, Fijnheer R, Voorberg J. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2005;93:267-274.
82. Soejima K, Matsumoto M, Kokame K, et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood. 2003;102:3232-3237.
83. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpurahemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005;3:1432-1436.
84. George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher. 2006;21:49-56.